114 related articles for article (PubMed ID: 30768573)
1. Plasma Pancreastatin Predicts the Outcome of Surgical Cytoreduction in Neuroendocrine Tumors of the Small Bowel.
Woltering EA; Voros BA; Beyer DT; Thiagarajan R; Ramirez RA; Mamikunian G; Boudreaux JP
Pancreas; 2019 Mar; 48(3):356-362. PubMed ID: 30768573
[TBL] [Abstract][Full Text] [Related]
2. Plasma Neurokinin A Levels Predict Survival in Well-Differentiated Neuroendocrine Tumors of the Small Bowel.
Woltering EA; Voros BA; Thiagarajan R; Beyer DT; Ramirez RA; Wang YZ; Mamikunian G; Boudreaux JP
Pancreas; 2018 Aug; 47(7):843-848. PubMed ID: 29939909
[TBL] [Abstract][Full Text] [Related]
3. Elevated Plasma Pancreastatin, but Not Chromogranin A, Predicts Survival in Neuroendocrine Tumors of the Duodenum.
Woltering EA; Beyer DT; Thiagarajan R; Ramirez RA; Wang YZ; Ricks MJ; Boudreaux JP
J Am Coll Surg; 2016 Apr; 222(4):534-42. PubMed ID: 26827125
[TBL] [Abstract][Full Text] [Related]
4. Elevated Serum Pancreastatin Is an Indicator of Hepatic Metastasis in Patients With Small Bowel Neuroendocrine Tumors.
Khan TM; Garg M; Warner RR; Uhr JH; Divino CM
Pancreas; 2016 Aug; 45(7):1032-5. PubMed ID: 26684860
[TBL] [Abstract][Full Text] [Related]
5. Aggressive Surgical Approach to the Management of Neuroendocrine Tumors: A Report of 1,000 Surgical Cytoreductions by a Single Institution.
Woltering EA; Voros BA; Beyer DT; Wang YZ; Thiagarajan R; Ryan P; Wright A; Ramirez RA; Ricks MJ; Boudreaux JP
J Am Coll Surg; 2017 Apr; 224(4):434-447. PubMed ID: 28088602
[TBL] [Abstract][Full Text] [Related]
6. It Is Time to Rethink Biomarkers for Surveillance of Small Bowel Neuroendocrine Tumors.
Tran CG; Sherman SK; Scott AT; Ear PH; Chandrasekharan C; Bellizzi AM; Dillon JS; O'Dorisio TM; Howe JR
Ann Surg Oncol; 2021 Feb; 28(2):732-741. PubMed ID: 32656719
[TBL] [Abstract][Full Text] [Related]
7. A single institution's experience with surgical cytoreduction of stage IV, well-differentiated, small bowel neuroendocrine tumors.
Boudreaux JP; Wang YZ; Diebold AE; Frey DJ; Anthony L; Uhlhorn AP; Ryan P; Woltering EA
J Am Coll Surg; 2014 Apr; 218(4):837-44. PubMed ID: 24655881
[TBL] [Abstract][Full Text] [Related]
8. Survival and prognostic factors in well-differentiated pancreatic neuroendocrine tumors.
Boyar Cetinkaya R; Vatn M; Aabakken L; Bergestuen DS; Thiis-Evensen E
Scand J Gastroenterol; 2014 Jun; 49(6):734-41. PubMed ID: 24679166
[TBL] [Abstract][Full Text] [Related]
9. Liver-directed surgery of neuroendocrine metastases: What is the optimal strategy?
Maxwell JE; Sherman SK; O'Dorisio TM; Bellizzi AM; Howe JR
Surgery; 2016 Jan; 159(1):320-33. PubMed ID: 26454679
[TBL] [Abstract][Full Text] [Related]
10. Neuroendocrine tumors (NETs) of unknown primary: is early surgical exploration and aggressive debulking justifiable?
Wang YZ; Chauhan A; Rau J; Diebold AE; Opoku-Boateng A; Ramcharan T; Boudreaux JP; Woltering EA
Chin Clin Oncol; 2016 Feb; 5(1):4. PubMed ID: 26932428
[TBL] [Abstract][Full Text] [Related]
11. A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin, neurokinin A) for neuroendocrine tumor detection.
Modlin IM; Drozdov I; Alaimo D; Callahan S; Teixiera N; Bodei L; Kidd M
Endocr Relat Cancer; 2014 Aug; 21(4):615-28. PubMed ID: 25015994
[TBL] [Abstract][Full Text] [Related]
12. Neuroendocrine tumours of the small bowel: interpretation of raised circulating chromogranin A, urinary 5 hydroxy indole acetic acid and circulating neurokinin A.
Ardill JE; Armstrong L; Smye M; Doherty R; McCance DR; Johnston BT
QJM; 2016 Feb; 109(2):111-5. PubMed ID: 25979268
[TBL] [Abstract][Full Text] [Related]
13. Serum pancreastatin: the next predictive neuroendocrine tumor marker.
Rustagi S; Warner RR; Divino CM
J Surg Oncol; 2013 Aug; 108(2):126-8. PubMed ID: 23775817
[TBL] [Abstract][Full Text] [Related]
14. Chromogranin A predicts survival for resected pancreatic neuroendocrine tumors.
Shanahan MA; Salem A; Fisher A; Cho CS; Leverson G; Winslow ER; Weber SM
J Surg Res; 2016 Mar; 201(1):38-43. PubMed ID: 26850182
[TBL] [Abstract][Full Text] [Related]
15. Predicting Survival of Small Intestine Neuroendocrine Tumors: Experience From a Major Referral Center.
Kelly S; Aalberg J; Agathis A; Phillips K; Haile S; Haines K; Kang Kim M; Divino CM
Pancreas; 2019 Apr; 48(4):514-518. PubMed ID: 30946234
[TBL] [Abstract][Full Text] [Related]
16. Chromogranin As a Biochemical Marker of Neuroendocrine Tumors.
Lyubimova NV; Churikova TK; Kushlinskii NE
Bull Exp Biol Med; 2016 Mar; 160(5):702-4. PubMed ID: 27021085
[TBL] [Abstract][Full Text] [Related]
17. Surgical Management of Small Bowel Neuroendocrine Tumors: Specific Requirements and Their Impact on Staging and Prognosis.
Pasquer A; Walter T; Hervieu V; Forestier J; Scoazec JY; Lombard-Bohas C; Poncet G
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S742-9. PubMed ID: 26014153
[TBL] [Abstract][Full Text] [Related]
18. Surgical Treatment of NEN of Small Bowel: A Retrospective Analysis.
Watzka FM; Fottner C; Miederer M; Weber MM; Schad A; Lang H; Musholt TJ
World J Surg; 2016 Mar; 40(3):749-58. PubMed ID: 26822157
[TBL] [Abstract][Full Text] [Related]
19. [The diagnostic value of plasma chromogranin A in neuroendocrine tumors].
Yang XO; Li JN; Qian JM; Yang H; Chen Q; Lu L
Zhonghua Nei Ke Za Zhi; 2011 Feb; 50(2):124-7. PubMed ID: 21418832
[TBL] [Abstract][Full Text] [Related]
20. Recurrence and Survival Outcomes After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Small Bowel Adenocarcinoma.
Saxena A; Valle SJ; Liauw W; Morris DL
Anticancer Res; 2017 Oct; 37(10):5737-5742. PubMed ID: 28982894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]